Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals [Letter]

Sri Wahyuni Gayatri1 Department of Biochemistry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, IndonesiaCorrespondence[email protected]

https://orcid.org/0000-0002-9346-7931

Andi St Fahirah Arsal2 Department of Pharmacology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia

Wisudawan3 Department of Cardiology and Vaskuler, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia

References

Said KB, Alsolami A, Alreshidi FS, et al. Profiles of independent-comorbidity groups in senior COVID-19 patients reveal low fatality associated with standard care and low-dose hydroxychloroquine over antivirals. J Multidiscip Healthc. 2023;16:1215–1229. doi:10.2147/JMDH.S403700
PubMed Web of Science ®Google Scholar
Alotaibi M, Ali A, Bakhshwin D, et al. Effectiveness and safety of favipiravir compared to hydroxychloroquine for management of covid-19: a retrospective study. Int J Gen Med. 2021;14:5597–5606. doi:10.2147/IJGM.S329881
PubMed Web of Science ®Google Scholar
Saghir SAM, Algabri NA, Alagawany MM, et al. Chloroquine and hydroxychloroquine for the prevention and treatment of covid-19: a fiction, hope or hype? An updated review. Ther Clin Risk Manag. 2021;17:371–387. doi:10.2147/TCRM.S301817
PubMed Web of Science ®Google Scholar
Panda PK, Singh BO, Moirangthem B, et al. Antiviral combination clinically better than standard therapy in severe but not in non-severe covid-19. Clin Pharmacol Adv Appl. 2021;13:185–195. doi:10.2147/CPAA.S325083
PubMed Web of Science ®Google Scholar

Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals [Letter]

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals [Letter]

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date